Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huawei Chen

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Blood|December 24, 2013
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemiaErika K Keeton, Kristen McEachern, Keith S Dillman, et al.
Cancer Immunology Research|August 9, 2018
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung CancerDennis O Adeegbe, Shengwu Liu, Maureen M Hattersley, et al.
Cancer Cell|December 8, 2009
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumorsMichael Hedvat, Dennis Huszar, Andreas Herrmann, et al.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
The Journal of Infectious Diseases|March 2, 2023
Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and MarinesPeifang Sun, Corey A Balinsky, Le Jiang, et al.
Cancer Research|October 10, 2018
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast CancerZebin Wang, Shaun E Grosskurth, Tony Cheung, et al.
Journal of Medicinal Chemistry|April 17, 2020
Discovery of (2<i>R</i>)-<i>N</i>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<i>H</i>-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 InhibitorQibin Su, Erica Banks, Geraldine Bebernitz, et al.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Nature Chemical Biology|October 25, 2016
Potent and selective bivalent inhibitors of BET bromodomainsMichael J Waring, Huawei Chen, Alfred A Rabow, et al.
ACS Chemical Biology|October 19, 2018
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6William McCoull, Tony Cheung, Erica Anderson, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Blood|December 24, 2013
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemiaErika K Keeton, Kristen McEachern, Keith S Dillman, et al.
Cancer Immunology Research|August 9, 2018
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung CancerDennis O Adeegbe, Shengwu Liu, Maureen M Hattersley, et al.
Cancer Cell|December 8, 2009
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumorsMichael Hedvat, Dennis Huszar, Andreas Herrmann, et al.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
The Journal of Infectious Diseases|March 2, 2023
Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and MarinesPeifang Sun, Corey A Balinsky, Le Jiang, et al.
Cancer Research|October 10, 2018
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast CancerZebin Wang, Shaun E Grosskurth, Tony Cheung, et al.
Journal of Medicinal Chemistry|April 17, 2020
Discovery of (2<i>R</i>)-<i>N</i>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<i>H</i>-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 InhibitorQibin Su, Erica Banks, Geraldine Bebernitz, et al.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Nature Chemical Biology|October 25, 2016
Potent and selective bivalent inhibitors of BET bromodomainsMichael J Waring, Huawei Chen, Alfred A Rabow, et al.
ACS Chemical Biology|October 19, 2018
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6William McCoull, Tony Cheung, Erica Anderson, et al.
Pageof 15